In two short months the number of publicly-traded bioinformatics companies has jumped from zero to four. Herewith, a quick take on valuations to date.
Lion and Compugen debuted in August, Genomica in September, and InforMax in October. And at press time their combined market capitalization was an impressive $2.86 billion — not bad for companies with aggregate annual revenues of less than $30 million. As a group the share price/revenue ratio is about 105.